Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.

Eli Lilly and Company announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival ...

Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster ...

One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...

While this adds competition to a market currently controlled by Eli Lilly LLY 0.13%increase; green up pointing triangle and Novo Nordisk, it also reinforces the dominance of the makers of Wegovy ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Per a news release, Eli Lilly's Zepbound is more effective than Novo Nordisk's Wegovy The weight-loss drug market is about to get even more crowded. Eli Lilly & Co (NYSE:LLY) stock is up 2.2% at $ ...

Eli Lilly said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the two weekly injections. The findings ...